Can a bladder rinse before surgery keep bladder cancer at bay?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed and dated informed consent. * Low- or intermediate-risk non-muscle-invasive bladder cancer (NMIBC) meeting one of the following definitions: * Low-risk NMIBC: Primary, solitary, Ta, low-grade, 0.5 cm to 3 cm. * Intermediate-risk NMIBC (low-to-intermediate risk subgroup per IBCG classification): * Primary multifocal (\<10 lesions), Ta, low-grade, 0.5 cm to 3 cm; * Recurrent solitary, Ta, low-grade, 0.5 cm to 3 cm; or * Recurrent multifocal (\<10 lesions), Ta, low-grade, \>1 year after previous recurrence. * Men and women aged 18 years or older. * Negative pregnancy test at screening for women of childbearing potential. * Women of childbearing potential must agree to use highly effective contraception methods throughout study participation; men of childbearing potential must refrain from donating sperm during the study. * Ability to retain bladder contents for 2 hours. Exclusion Criteria: * Patient with non-papillary tumor appearance at the time of initial cystoscopy. * Previous history of T1 or high-grade disease in recurrent tumors. * Patients with T1 or high-grade non-muscle invasive papillary bladder cancer (NMIBC). * Previous intravesical BCG immunotherapy. * Patients with any other cancer diagnosis within the last 5 years (except for skin basalioma). * Acute urinary tract infection requiring antibiotic treatment. * Prior radiotherapy or systemic chemotherapy. * WHO performance status of 3 or 4. * Any other investigational agent or non-marketed product within one month prior to Visit 1 and during the trial. * Known active HIV infection, defined as detectable HIV viral load at screening. * Active hepatitis B virus (HBV) infection, defined as hepatitis B surface antigen (HBsAg) positivity with detectable HBV DNA at screening. * Active hepatitis C virus (HCV) infection, defined as anti-HCV antibody positivity with detectable HCV RNA at screening in a patient not on stable antiviral treatment. * Any concurrent illness that may render a participant ineligible or limit compliance with study requirements. * Previously enrolled in this trial.